Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US2546041011
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00W9MJK79
IRON
Disc Medicine Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Disc Medicine Inc
ISIN
US2546041011
TICKER
IRON
MIC
XNAS
REUTERS
IRON.OQ
BLOOMBERG
IRON US
Thu, 27.02.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the fourth quarter and full year ended Dec...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.01.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of its upsized underwritten offering of sha...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.01.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its Type C meetin...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.01.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the grant of an inducement equity award to a new employee, effe...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.01.2025       Disc Medicine
US2546041011

WATERTOWN, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today outlined its recent pipeline and operational progress and strategic prior...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.12.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today spotlights 8 posters presented at the ASH 2024 annual meeting in San Dieg...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.12.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., Dec. 08, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive updated results from a Phase 1b trial of DISC-0974 in...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.11.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the third quarter ended September 30, 2024...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.11.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its end-of-Phase...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Fri, 25.10.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive additional data from an ongoing Phase 1b study of DISC...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 11.10.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced upcoming clinical data to be presented at the 2024 American Soc...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Fri, 30.08.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at f...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.08.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the second quarter ended June 30, 2024....
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.06.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an underwritten offering of 4,944,000 sh...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.05.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its hematolo...
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.05.2024       Disc Medicine
US2546041011

WATERTOWN, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the first quarter ended March 31, 2024....
Read more
Disc Medicine
Technical Analysis Termsheets Terminal
Permalink